QR Code

Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia®) in Japanese patients with primary immunodeficiency diseases

This phase 3 open-label study (jRCT2031210457; NCT05150340; January 2022–August 2023) evaluated pharmacokinetics, safety and tolerability, and efficacy of recombinant hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% in Japanese patients with primary immunodeficiency diseases (PID) t...

Full description

Saved in:
Main Authors: Hirokazu Kanegane, Masataka Ishimura, Eisuke Suganuma, Tomoyuki Imagawa, Takayuki Hoshina, Tomoki Kawai, Hidenori Ohnishi, Satoshi Okada, Chihiro Suzuki, Kentarou Kudou, Sharon Russo-Schwarzbaum, Immanuel Freedman, Barbara McCoy, Zhaoyang Li, Atsushi Kuga
Format: Artigo
Language:Inglês
Published: Taylor & Francis Group 2026-02-01
Series:Immunological Medicine
Subjects:
MeSH terms: immunoglobulins
pharmacokinetics
primary immunodeficiency diseases
Facilitated subcutaneous immunoglobulin
recombinant hyaluronidase
inborn errors of immunity
Online Access:https://www.tandfonline.com/doi/10.1080/25785826.2025.2607878
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items